Biotech Stocks 2014: The Best, Worst and Fastest-Growing

NEW YORK (TheStreet) -- Once again, biotech stocks greatly outperformed the broader market in 2014.

To give you the wide view, the  iShares Nasdaq Biotechnology ETF (IBB) gained 34% while the SPDR S&P Biotech ETF (XBI) , weighted more to small-cap stocks, rose 43%. The benchmark S&P 500 closed out the year with an 11% gain. 

XBI Chart

 

The 10 best-performing biotech and drug stocks in 2014:

  1. Avanir Pharmaceuticals (AVNR)    405%
  2. OvaScience (OVAS)                     384%
  3. Agios Pharmaceuticals (AGIO)      384%
  4. Bluebird Bio (BLUE)                     368%
  5. Receptos (RCPT)                         323%
  6. TG Therapeutics (TGTX)               306%
  7. Prosensa (RNA)                           302% 
  8. Pernix Therapeutics (PTX)            273%
  9. Achillion Pharma (ACHN)             269%
  10. Amicus Therapeutics (FOLD)        254%

Twenty-eight biotech and drugs stocks grew their market caps to $1 billion or more in 2014. Here's the top 10:

           Stock                        Market Cap        % Growth in Market Cap

  1. Receptos                    $3.8 billion                     613% 
  2. OvaScience                $1.05 billion                    574%
  3. Avanir Pharma            $3.3 billion                     543%
  4. Bluebird Bio               $2.9 billion                      476%
  5. Agios Pharma             $4.1 billion                     450%
  6. Achillion Pharma         $1.2 billion                     283%
  7. PTC Therapeutics        $1.5 billion                     277%
  8. Chimerix                    $1.4 billion                     268%
  9. Tetraphase                 $1.2 billion                     258%
  10. Horizon Pharma          $1.5 billon                      205%

The 10 worst-performing biotech and drugs stocks in 2014: 

  1. Nymox (NYMX)                         -93%
  2. Elbit Imaging (EMITF)               -92%
  3. Sophiris Bio (SPHS)                   -85%
  4. WaferGen BioSystems (WGBS)   -85%
  5. Rock Creek Pharmac (RCPI)       -84%
  6. Nanosphere (NSPH)                   -83%
  7. Cyclacel Pharma (CYCC)             -83%
  8. Cytori Therapeutics (CYTX)         -81%
  9. Regado BioSciences (RGDO)       -81%
  10. BioLife Solutions (BLFS)             -81%

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

This Market is Treacherous: Cramer's 'Mad Money' Recap (Thursday 12/11/18)

This Market is Treacherous: Cramer's 'Mad Money' Recap (Thursday 12/11/18)

Real Money Video Wrap: Volatility Reigns

Real Money Video Wrap: Volatility Reigns

Nvidia Shares Fall as SoftBank Reportedly Plans to Sell Its Stake

Nvidia Shares Fall as SoftBank Reportedly Plans to Sell Its Stake

Chart of the Day: McDonald's Management Maneuvers Amid Taxes, Tariffs

Chart of the Day: McDonald's Management Maneuvers Amid Taxes, Tariffs

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction